Related Experiment Videos
Summary
Peritoneovenous shunts (PVS) can be a life-saving treatment for ascites in cirrhosis patients. Proper management, including using epsilon-aminocaproic acid (EACA), prevents dangerous post-shunt coagulopathy (PSC).
Area of Science:
- Hepatology
- Surgical Complications
- Coagulation Disorders
Background:
- Cirrhosis patients with ascites historically faced a grim prognosis, with high mortality rates within months of diagnosis.
- Peritoneovenous shunts (PVS) offer a treatment option, but concerns about post-shunt coagulopathy (PSC) have limited their use.
- Ascites development is linked to diminished blood volume and abnormal sodium retention, highlighting the need for effective fluid management.
Purpose of the Study:
- To investigate the mechanisms behind post-shunt coagulopathy (PSC) following peritoneovenous shunt (PVS) placement for cirrhotic ascites.
- To evaluate the efficacy of epsilon-aminocaproic acid (EACA) and clotting factors in preventing and treating PSC.
- To demonstrate that PSC is a distinct entity from disseminated intravascular coagulopathy (DIC) and can be effectively managed.
Main Methods:
- Analysis of patient data from over 150 PVS procedures, comparing outcomes with and without ascitic fluid management.
- In vitro studies using thromboelastogram (TEG) to assess the effect of ascitic fluid on blood coagulation.
- Administration of epsilon-aminocaproic acid (EACA) and clotting factors to patients experiencing or at risk of PSC.
Main Results:
- Disposal of ascitic fluid during surgery significantly reduced the incidence of PSC, from 7/98 cases to 1.3% (1/77) mild cases.
- Ascitic fluid in vitro promotes clot lysis, a process counteracted by EACA, which also normalizes TEG results.
- EACA and clotting factors effectively arrested coagulopathy in treated patients, preventing mortality from PSC.
Conclusions:
- Post-shunt coagulopathy (PSC) is a distinct complication of peritoneovenous shunts (PVS) caused by peritoneal serosa-secreted tissue plasminogen activator (TPA).
- Epsilon-aminocaproic acid (EACA) is the effective antidote for PSC, differing from heparin used for disseminated intravascular coagulopathy (DIC).
- Proper management, including ascitic fluid disposal and EACA administration, eliminates PSC as a deterrent to PVS, improving outcomes for cirrhotic patients.